DISCLAIMER: CONSULT WITH A DOCTOR BEFORE DECIDING ON A TREATMENT PLAN FOR DEMENTIA OR ANY OTHER DISEASE.
WE’VE INCLUDED LINKS BELOW TO PRODUCTS THAT HAVE A REPUTATION FOR BEING OF HIGH-QUALITY AND APPROPRIATE FOR HOLISTIC TREATMENT. THESE AFFILIATE LINKS HELP FUND THIS WEB SITE AND KEEP IT GOING.
Introduction to Gut Microbiome Cure for Dementia
Research into the role of probiotics in the treatment of central nervous system disorders and autoimmunity diseases like Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease), Parkinson’s Disease, Lewy Body dementia, and Alzheimer’s is all the rage right now. These studies that delve into the gut-brain/nervous system connection has yielded some interesting results that could lead to a cure for Lewy body dementia and other related diseases. Recent studies have shown that microbiota in the gastrointestinal tract are directly linked to the development of dementia and inflammatory diseases affecting the nervous system because tiny infectious microorganisms can trigger metabolic issues that cause inflammation and a variety of disease states. A healthy gut flora can heal inflammatory conditions. So scientists are starting to recommend that patients with Parkinson’s, Lewy Body Dementia, Multiple Sclerosis, or Amyotrophic Lateral Sclerosis take probiotics and use other alternative dementia treatments to cure Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson’s Disease, and Lewy Body Dementia .
In the early 1990’s, researchers at the University of Nebraska Medical Center published a paper that found a correlation between major gastrointestinal issues and a heightened risk of developing of Parkinson’s disease. The gastrointestinal upsets that led to PD included common complaints such as:
- Acid Reflux
- Gut Inflammation
- More 
Interestingly, the scientists also discovered that Parkinsonian motor conditions were correlated with vagus nerve issues in participants as well. Some scientists think that disease progression in Parkinson’s patients is directly linked to a deterioration of the vagus nerve. This is the tenth cranial nerve that provides parasympathetic control of internal organs such as the heart, lungs, and digestive system. It is the longest autonomic nervous system nerve, running all the way from the brain down to the gut. The vagus nerve demonstrates the obvious connection between the brain, cognition, mood, and gut health. This nerve and its implications for the gut microbiome of patients has been studied in terms of its influence on all of the following: Parkinson’s, Lewy Body Dementia, Multiple Sclerosis, Alzheimer’s, and Lou Gehrig’s disease. The role of the vagus nerve in this disease indicate that it might be worthwhile for patients to self-medicate with a substance like DMSO (dimethylsulfoxide) that has the ability to heal nerve tissues and also fight infectious organisms 
In one study, vagus nerve stimulation reduced demyelination and sped up the re-myelination of nerve fibers in MS patients. Scientists are studying underlying reasons why this may occur including the role of leukocytes and oligodendrocytes in vagus nerve stimulation, but the mechanism of action is still not well understood. 
Another important study examined the impact of cutting the vagus nerve (vagotomy) on Parkinson’s patients. Scientists theorize that an enteric neurotropic pathogen may seek passage into the brain via the vagus nerve. Infection of the brain via the vagal nerve is a process that could take over 20 years with the infectious organism slowly making its way from the gut to the Central Nervous System. If Parkinson’s and related diseases like Lewy body dementia, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis are all indeed caused by an infectious pathogen that travels via the vagus nerve tissues from gut to brain, patients may be able to use a Miracle Mineral Solution (MMS) combined with dimethylsulfoxide (DMSO–see above) treatment protocol as a cure for Parkinson’s Disease and other related diseases 
Because vagus nerve stimulation has been established as a viable treatment method for treatment resistant epilepsy (therapy-refractory epilepsy) and treatment resistant depression, scientists have also attempted to use vagus nerve stimulation to treat Alzheimer’s disease. Results of studies on vagus nerve stimulation in Alzheimer’s patients has been promising. The effects have promoted enhanced cognition in Alzheimer’s patients and long-term tolerability of vagus nerve stimulation has been supported by research. Though it is possible to have a device surgically implanted into the body for vagus nerve stimulation, there are also non-surgical options available to patients today to do vagus nerve stimulation . Though doctors will recommend surgical implantation of a device that stimulates the vagus nerve, it is possible to use specialized machines that are manually applied to the vagus nerve as needed. Auricular acupuncture therapies, lasers, or electrical stimulation of the vagus nerve using other devices may have the same effect as vagus nerve stimulation from a surgically implanted device 
Postmortem examinations of patients with both Lewy body dementia and Parkinson’s disease have revealed Lewy bodies (a hallmark of both LBD and PD) in the substantia nigra as well as (possibly) in the locus ceruleus, dorsal raphe, substantia innominata, and the vagus nerve. Scientists have noted that the earliest sites affected by Lewy body dementia are the olfactory bulb, the vagus nerve, the peripheral autonomic nervous system, the enteric nervous system, and the brain stem. 
Vagus nerve stimulation has also been used as a well-tolerated treatment for drug-resistant partial seizures. For some people, vagus nerve stimulation may function as a cure for epilepsy, Parkinson’s, Lewy body dementia, or any of the other related diseases. Adverse effects of vagus nerve stimulation include:
- Dyspnea (shortness of breath)
- Paresthesia (abnormal skin sensations with no apparent physical cause)
- Headache 
Parkinson’s disease patients also tend to have issues related to their rectum and pelvic floor, but patients with Lewy body dementia are even more likely to suffer from issues related to their gastrointestinal system than patients with Parkinson’s. Neurodegenerative diseases such as Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson’s, and Lewy body dementia famously cause gastrointestinal issues. Research has demonstrated that Lewy Body Dementia is correlated with acute intestinal obstructions in older populations. Studies have shown that ALS patients suffer from leaky gut syndrome and research into the gut microbiome in Multiple Sclerosis sufferers has demonstrated a link between microbial imbalances in the intestines and disease progression. Even Alzheimer’s disease seems to be linked with gut microbiome issues. The use of probiotics as well as colostrum to cure Lewy body dementia by repairing damage that’s been done to the gut is an important part of any Dementia Protocol as well as protocols designed to reverse Multiple Sclerosis and Amyotrophic Lateral Sclerosis .
Research has revealed that there are dopamine receptors in the esophageal sphincter (a band of muscle tissue that opens and closes in response to the presence or absence of food in the stomach/esophagus). More recent research conducted in 2011 at the University of Tennessee Health Science Center added salivation issues and gastroparesis (where the stomach does not empty its contents properly) to the list of problems that are commonly found in patients suffering from Parkinson’s and Lewy body dementia which is due perhaps in part, to dysfunctions in the dopaminergic system in Parkinson’s and Lewy body dementia patients. MS patients often have trouble swallowing. Swallowing difficulties point to a possible link between iodine deficiency and Multiple Sclerosis because difficulty swallowing is one of the symptoms of iodine deficiency. 
According to research that’s been done comparing the microbiome of healthy patients with the microbiome of Parkinson’s patients, Parkinson’s patients have about 23% less Prevotella species in their guts. In fact, studies have shown that fewer Prevotella species in the gut significantly increases the incidence of Parkinson’s. 
Additionally, the research found that Parkinson’s patients have significantly more bacteria in their guts from the Enterobacteriaceae family. This family of organisms includes: Escherichia coli, Yersinia pestis, Klebiella, Shigella, Citrobacter, Salmonella, Proteus, Serratia, and Enterobacter. These organisms are well-known for causing a variety of diseases in the digestive system and throughout the body .
Additionally, the specific probiotic species that helps the body remove toxic chemicals from the body exist at a low level in Parkinson’s patients. This is an important finding because some researchers believe that Parkinson’s disease develops as a result of exposure to certain toxic chemicals and/or heavy metals. The families of probiotics that stood out as particularly deficient in Parkinson’s and Lewy body dementia patients included:
- Verrucomicorbiaceae 
There’s a link between the presence of Lewy bodies and the number of pathogenic, bad bacteria living in the gut. Lewy bodies in the substantia nigra region of the brain stem damage the neurons that produce dopamine which has been blamed for the progression of Parkinson’s. Lewy bodies that develop in other areas of the brain, beyond the substantia nigra are blamed for the symptoms of dementia that characterize Lewy body dementia .
A high-quality probiotic with at least 15 billion CFU is recommended for Parkinson’s, Lewy body dementia, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis patients to promote the colonization of a healthy gut flora. Those who are hoping to cure Parkinson’s Disease or any of the other related diseases should use more than just one treatment strategy and combine various treatments into a protocol aimed at not only restoring gut health, but also treating infectious organisms that may be living in the gut and in the vagus nerve and the brain.
Small Intestine Bacteria Overgrowth (SIBO) and Parkinson’s
One study examined the potential for Small Intestine Bacteria Overgrowth (SIBO) that could develop as a result of motility issues in the small intestine and found that SIBO is extremely prevalent in Parkinson’s patients. 
Stem Cell Cure for Dementia
In addition to the use of probiotics and vagus nerve stimulation as possible treatment strategies that address the gut-brain connection via the vagus nerve, stem cell therapies also offer an important option for Parkinson’s, Lou Gehrig’s disease, Multiple Sclerosis, Lewy Body Dementia, and epilepsy patients to consider. Below is a treatment center in India that offers Stem Cell Therapy for Lewy Body Dementia, Parkinson’s Disease, Multiple Sclerosis, and other related diseases. Stem cell therapies are available in a number of different countries outside of the United States in high-tech facilities that are designed specifically to cater to Americans who are doing medical tourism. 
Plot no. 19, Sector no. 40, Next to Sea Woods Grand Central Station (W), Opp.Konkan Rail Vihar, Off. Palm beach road, Nerul (west), Navi Mumbai – 400706. Maharashtra. India.
+91 9920 200 400
Rife Machine Treatment for Dementia
While treatment with a Rife machine such as a Spooky2 would not be able to restore the missing bacterial flora (Prevotella, for example), it is possible that it could keep overgrowth of undesirable bacteria at bay. A Rife machine is an electronic device that creates specific vibratory frequencies that can resonate with specific bacteria, viruses, or fungi to cause them to explode. Royal Rife worked in University settings in California before his machine became famous for its ability to kill cancer. After word got out about his machine, the FDA confiscated all Rife machines and made it illegal to buy or even build such a device. 
The Rife machine is regularly used by people all over the world to cure diseases such as Lyme disease, cancer, diabetes, AIDs, herpes, malaria, etc. Many diseases that are considered to be “degenerative” diseases were found to be infectious diseases by Rife who used dark-field microscopy rather than traditional microscopes to view microorganisms. 
Other Important Links:
 Alkasir, R., Li, J., Li, X., Jin, M., Zu, B. (2007). Human Gut Microbiota: the links with dementia development. Retrieved December 28, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/27866330
 Adams, C. (2017). Why Parkinson’s is Linked to Abnormal Gut Bacteria. Retrieved January 7, 2019 from https://www.realnatural.org/parkinsons-disease-gut-bacteria/
 Gabrielli, M., Bonazzi, P., Scarpelli, E. et al. (2011). Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson’s Disease. Retrieved January 7, 2019 from https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.23566
 Gerber, R. (2001). Vibrational Medicine: The #1 Handbook of Subtle-Energy Therapies. Bear & Company: Rochester, VT.
 Pilkington, M. (2003). Dr. Rife’s oscillating beam ray. Retrieved March 20, 2018 from https://www.theguardian.com/science/2003/apr/03/research.science1
 Alternative Medicine Truth (2007). Rife Therapy and Treatment Explained. Retrieved March 20, 2018 from http://alternativemedicinetruth.blogspot.mx/2007/03/rife-therapy-and-treatment-explained.html
 Tankou, S. K., Regev, K., Healy, B. C., Cox, L. M., Tjon, E., Kivisakk, P. et al. (2018). Investigation of probiotics in multiple sclerosis. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/29307299
 Tankou, S. K., Regev, K. , Healy, B. C., Tjon, E., Laghi, L., Cox, L. M. et al. (2018). A probiotic modulates the microbiome and immunity in multiple sclerosis. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/29679417
 Wright, M. L., Fournier, C., Houser, M. C., Tansey, M., Glass, J., Hertzberg, V. S. (2018). Potential Role of the Gut Microbiome in ALS: A Systematic Review. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/29925252
 PaleoLeap (2019). The Health Benefits of Butyrate: The Anti-Inflammatory Fat. Retrieved June 24, 2019 from https://paleoleap.com/butyrate-anti-inflammatory-fat/
 (2017). Dementia with Lewy bodies (DLB) patients suffer more frequently from gastrointestinal dysfunction. Retrieved June 24, 2019 from https://www.wfneurology.org/2017-09-18-wcn-dlb-patients-suffer-more-from-gastrointestinal-dysfunction
 Shaoping, W., Jianxun, Y., Yong-guo, Z., Jingsong, Z., Jun, S. (2015). Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425962/
 Levinthal, D. J., Rahman, A. Nusrat., S., O’Leary, M., Heyman, R., Klaus, B. (2013). Adding to the Burden: Gastrointestinal Symptoms and Syndromes in Multiple Sclerosis. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791579/
 Kirby, T. O., Ochoa-Reparaz, J. (2018). The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163724/
 Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019). Antibiotics, gut microbiota, and Alzheimer’s disease. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530014/
 Boroch, A. (2019). How I Cured My Multiple Sclerosis (MS) with Diet and How You Can Too. Advice from a Naturopath. Retrieved June 24, 2019 https://www.furtherfood.com/cure-multiple-sclerosis-naturally-heal-ms-diet-supplements-naturopath-advice/
 Hamlin, N. (2017). Vagus nerve stimulation attenuates demyelination and accelerates remyelination in a Lysolecithin-induced multiple sclerosis model. Retrieved June 24, 2019 from https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200835/nicole.hamlin.vagus.nerve.stimulation.attenuates.demyelination.and.accelerates.html
 Walter, U., Tsiberidou, P., Kersten, M., Storch, A., Lohle, M.(2018). Atrophy of the Vagus Nerve in Parkinson’s Disease Revealed by High-Resolution Ultrasonography. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170613/
 Svensson, E., Horvath-Puho, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., Sorensen, H. T. (2015). Vagotomy and subsequent risk of Parkinson’s disease. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/26031848/
 Sjogren, M. J., Hellstrom, P. T., Jonsson, M. A., Runnerstam, M., Silander, H. C., ben-Menachem, E. (2002). Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer’s disease: a pilot study. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/12444809
 Merrill, C.A., Jonsson, M. A., Minthon, L., Ejnell, H., C-son Silander, H., Blennow, K., Karlsson, M. et al. (2006). Vagus nerve stimulation in patients with Alzheimer’s disease: Additional follow-up results of a pilot study through 1 year. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/16965193
 Howard, A. C., Chawla, J. (2018) What are the postmortem findings in dementia with Lewy bodies (DLB)? Retrieved June 24, 2019 from https://www.medscape.com/answers/1135041-95818/what-are-the-postmortem-findings-in-dementia-with-lewy-bodies-dlb
 Donaghy, P. C. & McKeith, I. G. (2014). The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Retrieved June 24, 2019 from https://alzres.biomedcentral.com/articles/10.1186/alzrt274
 Panebianco, M., Rigby, A., Weston, J. Marson, A. G. (2015). Vagus nerve stimulation for partial seizures. Retrieved June 24, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/25835947
 Panchison, D. (2019). Repairing the Nervous System with Stem Cells. Retrieved June 24, 2019 from https://stemcells.nih.gov/info/Regenerative_Medicine/2006Chapter3.htm